M0 at presentation (N = 90) |
M1 (N = 68) |
Total (N = 158) | |
---|---|---|---|
Year of Metastasectomy | |||
Median | 1999 | 1998 | 1999 |
Range | (1991–2005) | (1990–2004) | (1990–2000) |
Metastatic Site | |||
BONE | 9 (10.0%) | 10 (14.7%) | 19 (12.0%) |
BOWEL | 1 (1.1%) | 0 (0.0%) | 1 (0.6%) |
BRAIN | 7 (7.8%) | 4 (5.9%) | 11 (7.0%) |
CONTRALATERAL ADRENAL | 3 (3.3%) | 5 (7.4%) | 8 (5.1%) |
HEART | 0 (0.0%) | 1 (1.5%) | 1 (0.6%) |
IPSILATERAL ADRENAL | 2 (2.2%) | 8 (11.8%) | 10 (6.3%) |
LIVER | 4 (4.4%) | 5 (7.4%) | 9 (5.7%) |
MUSCLE | 0 (0.0%) | 1 (1.5%) | 1 (0.6%) |
NON-REGIONAL NODES | 9 (10.0%) | 1 (1.5%) | 10 (6.3%) |
OMENTUM | 0 (0.0%) | 1 (1.5%) | 1 (0.6%) |
OTHER | 6 (6.7%) | 8 (11.8%) | 14 (8.9%) |
PANCREAS | 5 (5.6%) | 2 (2.9%) | 7 (4.4%) |
PULMONARY | 40 (44.4%) | 20 (29.4%) | 60 (38.0%) |
SKIN | 2 (2.2%) | 2 (2.9%) | 4 (2.5%) |
SPLEEN | 1 (1.1%) | 0 (0.0%) | 1 (0.6%) |
THYROID | 1 (1.1%) | 0 (0.0%) | 1 (0.6%) |
Metastatic Grade | |||
2 | 16 (17.8%) | 13 (19.1%) | 29 (18.4%) |
3 | 60 (66.7%) | 36 (52.9%) | 96 (60.8%) |
4 | 14 (15.6%) | 19 (27.9%) | 33 (20.9%) |
Metastatic Necrosis | |||
No | 57 (63.3%) | 38 (55.9%) | 95 (60.1%) |
Yes | 33 (36.7%) | 30 (44.1%) | 63 (39.9%) |
Metastatic Sarcomatoid | |||
No | 86 (95.6%) | 62 (91.2%) | 148 (93.7%) |
Yes | 4 (4.4%) | 6 (8.8%) | 10 (6.3%) |